Peptides vs SARMs vs TRT: How They Differ

Peptides, SARMs and TRT are often mentioned in the same breath because people use all three in the hope of building muscle, but they differ in chemistry, in where they act in the body, in the evidence behind them and in their legal status.

• SARMs (selective androgen receptor modulators) are small, non-steroidal chemicals, usually taken by mouth, that act on the same receptor as testosterone. None is an approved medicine.
• TRT (testosterone replacement therapy) is prescribed testosterone, an approved medicine for men with diagnosed hypogonadism.
• Peptides promoted for muscle, such as ipamorelin and CJC-1295, are short chains of amino acids that mostly signal the pituitary gland to release growth hormone. Most are unapproved.

A separate guide, Peptides vs Steroids, explains the chemical and mechanistic differences between peptide hormones and anabolic steroids. This guide adds SARMs and medical testosterone therapy to that comparison, and focuses on evidence and regulation. The muscle claims made about growth hormone peptides are examined in section 4.

This guide describes research and regulatory status only. It gives no doses or instructions and is not medical advice. Whether any treatment suits a particular person is a decision for a licensed clinician.

Testosterone acts on the androgen receptor in many tissues: muscle and bone, but also the prostate, skin, hair follicles and the brain. SARMs were developed from the late 1990s onward as non-steroidal molecules that would activate the receptor mainly in muscle and bone, in the hope of treating muscle wasting and osteoporosis with fewer effects on the prostate. Well-known examples include enobosarm (ostarine), LGD-4033 (ligandrol) and RAD140. Unlike testosterone, they are not steroids, and most are active when swallowed.

What trials showed. In early clinical trials, SARMs did increase lean body mass. In a 12-week phase 2 trial of 120 older men and postmenopausal women, enobosarm increased lean body mass and improved a measure of physical function compared with placebo [3]. In a 21-day trial in 76 healthy young men, LGD-4033 increased lean body mass but also suppressed total testosterone and lowered HDL (“good”) cholesterol, effects that reversed after stopping [4]. These trials were short and small, and no SARM went on to approval.

Regulatory status. As of 17 October 2026, no SARM had been approved by FDA. FDA states that SARMs cannot be legally marketed in the U.S. as a dietary supplement, and that products sold as supplements or “for research use only” are considered unapproved drugs. It lists liver injury and acute liver failure, and an increased risk of heart attack or stroke, among the serious problems linked to them [2].

What is actually in the bottle. When researchers bought 44 products sold online as SARMs and analysed them in 2016, only 23 (52%) contained a SARM. Seventeen contained other unapproved drugs, four contained no active compound, and only 18 had the amount stated on the label [1].

Liver injury. Case reports describe drug-induced liver injury in people taking SARMs bought online, often with a cholestatic pattern (impaired bile flow) similar to that seen with oral anabolic steroids, which can take weeks to months to resolve [6]. A 2025 systematic review identified 15 published cases of SARM misuse, all in men, and reported liver injury, heart problems, tendon damage and testosterone suppression [5]. Case reports cannot show how common these harms are, but they show what can happen.

Testosterone replacement therapy is the use of approved testosterone medicines, as gels, patches, injections, oral or buccal forms, for men with hypogonadism: testes that produce too little testosterone. FDA states that testosterone is approved solely for men who have low testosterone together with an associated medical condition [9].

Diagnosis comes first. The Endocrine Society's clinical guideline recommends diagnosing hypogonadism only in men with symptoms and signs of testosterone deficiency and testosterone levels that are unequivocally and consistently low, confirmed by repeating a fasting morning blood test. It recommends looking for the cause, aiming for testosterone in the mid-normal range during treatment, and monitoring symptoms, red blood cell levels and prostate cancer risk. It recommends against starting testosterone in men planning to father a child soon, and in men with conditions such as breast or prostate cancer, untreated severe sleep apnoea, or a recent heart attack or stroke [7].

The TRAVERSE trial. For years there was uncertainty about whether testosterone therapy raised the risk of heart attack and stroke. TRAVERSE, a randomised, double-blind, placebo-controlled trial, enrolled 5,246 men aged 45 to 80 with symptomatic hypogonadism and existing or high risk of cardiovascular disease. Over a mean follow-up of 33 months, the combined rate of cardiovascular death, non-fatal heart attack or non-fatal stroke was 7.0% with testosterone and 7.3% with placebo, meeting the test for non-inferiority. Atrial fibrillation, acute kidney injury and pulmonary embolism were more frequent with testosterone [8].

After reviewing TRAVERSE and blood-pressure monitoring studies, FDA announced class-wide labelling changes in February 2025. It removed the boxed-warning language about increased cardiovascular risk, added TRAVERSE results to labels, kept the limitation of use for age-related low testosterone, and required warnings about increased blood pressure [9].

TRT is not a muscle-building treatment for healthy men. Muscle gains seen in trials of high-dose testosterone in healthy men [10] involve hormone levels well above the normal range, which is anabolic steroid use rather than replacement, and carries the harms summarised in section 7.

Mechanism. Testosterone and SARMs both act directly on the androgen receptor, which sits inside cells and changes which genes are switched on. The peptides promoted for muscle work one step further upstream. GHRH analogues such as CJC-1295, sermorelin and tesamorelin, and ghrelin mimetics such as ipamorelin, GHRP-2, GHRP-6 and hexarelin, bind receptors on the surface of pituitary cells and prompt the release of growth hormone, which in turn raises IGF-1. The background is in Growth Hormone Secretagogues and Peptide Receptors.

Because peptides are broken down in the gut, most must be injected, whereas many SARMs are taken by mouth (see Oral vs Injected Peptides). A few peptides act on the testosterone axis itself: gonadorelin and kisspeptin signal the pituitary to release the hormones that tell the testes to make testosterone. They are research or specialist medicines, not muscle treatments.

Evidence. Growth hormone, the end product of the muscle peptides, increased lean body mass in randomised trials in healthy young adults, but did not improve strength or exercise capacity [12]. No published randomised trial has measured muscle or strength for ipamorelin, CJC-1295 or the related research peptides.

Regulation. Among growth hormone peptides, only tesamorelin had a current U.S. approval as of 17 October 2026, and that approval is for excess abdominal fat in adults with HIV-associated lipodystrophy [13]. FDA has placed GHRP-2, GHRP-6 and ipamorelin in a category of bulk substances that may present significant safety risks in compounding, and has noted serious adverse events reported with CJC-1295 [14]. For the wider picture, see Are Peptides Legal? and Approved vs Unapproved Peptides.

The table summarises the three groups as of 17 October 2026. It compares evidence and status, not suitability for any person.

WADA statuses are from the 2026 Prohibited List [15].

All three groups are prohibited at all times, in and out of competition, under the World Anti-Doping Agency's 2026 Prohibited List [15]:

• TRT: testosterone is listed under S1.1, anabolic androgenic steroids. An athlete with genuine, documented hypogonadism must apply for a therapeutic use exemption.
• SARMs: listed by name under S1.2, other anabolic agents, including andarine, enobosarm (ostarine), LGD-4033 (ligandrol), RAD140, S-23 and YK-11.
• Growth hormone peptides: listed under S2.2.4, growth hormone releasing factors, which names CJC-1295, sermorelin, tesamorelin, ipamorelin, GHRP-2, GHRP-6 and examorelin (hexarelin).
• Testosterone-stimulating peptides: gonadorelin and kisspeptin, with their analogues, are listed under S2.2.1 for male athletes.

The list also covers substances with a similar chemical structure or biological effect, so a compound being unnamed does not make it permitted. Contaminated or mislabelled products, common among SARMs [1], are not a defence under anti-doping rules. See WADA Peptide Rules and Peptides and Athletes.

The quality of safety evidence differs as much as the substances do.

• TRT has the most data: large randomised trials, labelled warnings and monitoring guidance, but only for men with diagnosed hypogonadism treated to normal levels [7][8]. Those data do not describe high-dose use for muscle.
• Testosterone and other steroids used above normal levels have well-documented harms. An Endocrine Society scientific statement links performance-enhancing drug use to an increased risk of death and to cardiovascular, psychiatric, hormonal, liver and kidney disorders [11].
• SARMs have short trial data, FDA warnings and a growing set of case reports of liver injury, with the added problem that products often do not contain what the label says [1][2][5]. The claim that they are a “safer steroid” has not been tested in long-term trials.
• Growth hormone peptides have almost no long-term safety data in healthy people. Known concerns from approved and related drugs include raised blood sugar and the unknown effects of prolonged IGF-1 elevation [13], plus impurity and immune risks in unregulated products [14].

No trial has compared these groups head to head, so statements that one is “safer” than another go beyond the evidence. A substance with fewer reported harms may simply have been studied less. For a broader framework, see Are Peptides Safe? and Understanding Evidence Levels.

What is the difference between peptides and SARMs?

SARMs are non-steroidal small molecules, usually taken by mouth, that act directly on the androgen receptor, the same receptor as testosterone. The peptides promoted for muscle are short amino-acid chains, usually injected, that signal the pituitary to release growth hormone. Neither group has approved muscle-building uses [2].

Are SARMs legal?

In the U.S., no SARM is an approved medicine, and FDA states they cannot be legally marketed as dietary supplements; products sold “for research use only” are treated as unapproved drugs [2]. Laws on possession differ by country. All SARMs are banned in sport [15].

Is TRT the same as taking steroids?

Testosterone is an anabolic steroid, but TRT aims to restore normal levels in men with diagnosed hypogonadism under medical monitoring [7]. Steroid misuse pushes levels well above normal and carries greater, well-documented risks [11].

Does TRT cause heart attacks?

In TRAVERSE, men with hypogonadism and high cardiovascular risk had a similar rate of major heart events on testosterone and placebo, although atrial fibrillation, acute kidney injury and pulmonary embolism were more frequent with testosterone [8]. Individual risk is a question for the prescribing clinician.

Are peptides safer than SARMs or TRT?

That cannot be stated on current evidence. TRT has large trials in a defined population; SARMs and growth hormone peptides have short or no trials and unreliable products. Less evidence of harm is not evidence of safety.

Can peptides replace TRT?

No peptide is approved as a replacement for testosterone therapy. Peptides such as gonadorelin and kisspeptin act on the hormone signals that control testosterone production and are studied in specialist settings, but treatment decisions for low testosterone belong with a clinician.